|
CONTACTS:
Applied NeuroSolutions
Ellen Hoffing, President, CEO, 847-573-8000
or
Investor Relations
Ryan Rauch, 847-573-8000
Applied NeuroSolutions Provides Update on Alzheimer's Disease Therapeutic Collaboration with Eli Lilly and Company
Included in updated Corporate Presentation on company website
Vernon Hills, IL August 8, 2007 – Applied NeuroSolutions, Inc. (OTC BB:APNS, www.appliedneurosolutions.com), a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer’s disease (AD), today announced its corporate presentation, which can be found on the company web site, has been revised to include an update on the progress of its collaboration with Eli Lilly and Company (NYSE:LLY).
“We are very pleased with the early successes achieved in our collaboration with Eli Lilly and Company that is a reflection of the strong teamwork and commitment,” said Ellen R. Hoffing, President and CEO of Applied NeuroSolutions. "As events warrant, we look forward to providing additional updates on the progress we are making in the development of novel therapeutics to treat AD."
Dr. Peter Davies, APNS founding scientist, added “I am thrilled to see the progress that has come from the unique combination of resources, expertise and commitment brought together in the APNS – Lilly collaboration. It is exciting and gratifying to be moving forward beyond the early stage discovery process and I am more optimistic than ever that this team can be successful in its mission to develop drugs that will halt the progression of Alzheimer’s disease by interfering with the early stages of tau pathology.”
About Applied NeuroSolutions:
Applied NeuroSolutions, Inc. (OTC BB:APNS - News) is developing diagnostics to detect Alzheimer's disease (AD) based on discoveries originating from the Albert Einstein College of Medicine and, in collaboration with Eli Lilly and Company, is seeking novel therapeutic compounds to treat the progression of the disease. Applied NeuroSolutions has discovered biomarkers that the company believes will aid in the development of effective AD treatments. Applied NeuroSolutions is focused on both a cerebrospinal fluid (CSF) diagnostic test and blood tests to detect AD at a very early stage. The CSF test can already differentiate AD patients from those with other diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be 30 million patients. For more information, visit www.appliedneurosolutions.com.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.
|
